OR WAIT null SECS
September 05, 2024
Article
Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.
September 04, 2024
This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.
August 25, 2024
Moderate to severe anemia was linked to an increase in cardiac arrest or stroke compared with normal hemoglobin levels in critically ill COVID-19 patients.
August 21, 2024
Across a statewide cohort, more than half of patients were unable to achieve iron deficiency resolution within 3 years.
August 20, 2024
A new recommendation statement cites a lack of current evidence to assess the benefits of iron deficiency screening and supplementation in pregnant individuals.
August 18, 2024
A randomized clinical trial found significant improvements in key blood parameters for anemia after grape syrup intervention compared with placebo.
August 15, 2024
Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.
August 14, 2024
Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.
August 12, 2024
Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.
August 11, 2024
Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.
